Zoledronate가 UMR-106 세포의 증식과 조골세포 형성에 미치는 영향
Zoledronate(Zometa®) inhibits the formation of osteoblast in rat osteoblastic cell line UMR-106
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The purpose of this study is to identify the effect of zoledronate(Zometa®), which is most common nitrogen containing bisphosphonate, on survival, proliferation, and differentiation of osteoblast. Material & Methods: Twenty four cell culture plates containing essential medium were seeded with UMR-106 cell lines, at density of 5 x 104 cells per plates. Each plates were incubated with 5% CO2 incubator at 37℃. Starting from 2 days after incubation, cell culture medias were replaced, and added with osteogenesis induction media and 0, 0.01, 0.1, 0.5, 1, 3μM of zoledronate(Zometa®), every 2 days, for 12 days. “Control group” was plates not added with zoledronate(0μM), and “experiment group” were plates added with different concentration of zoledronates(0, 0.01, 0.1, 0.5, 1, 3μM). Mature osteoblasts were identified with Alizarine Red staining, and protein samples were collected. Optical density was determined at wavelength of 405nm with ELISA reader. For viability analysis, cells were harvested and incubated with propidium iodide, and analysed with flow cytometry. Western blot technique was used to analyse Runx2 protein of osteoblast. Results: Secretion of bone matrix decreased as zoledronate concentration increased, and zoledronate did not effect survival rate of UMR-106 cells when measured with flow cytometer. Expression of Runx2 protein was inhibited as zoledronate concentration increased. Conclusion: From the results, we were able to identify that increase of zoledronate concentration inhibited differentiation of UMR-106 cell to osteoblast, without effecting quantity or survival rate.
Abstract
Purpose: The purpose of this study is to identify the effect of zoledronate(Zometa®), which is most common nitrogen containing bisphosphonate, on survival, proliferation, and differentiation of osteoblast. Material & Methods: Twenty four cell culture plates containing essential medium were seeded with UMR-106 cell lines, at density of 5 x 104 cells per plates. Each plates were incubated with 5% CO2 incubator at 37℃. Starting from 2 days after incubation, cell culture medias were replaced, and added with osteogenesis induction media and 0, 0.01, 0.1, 0.5, 1, 3μM of zoledronate(Zometa®), every 2 days, for 12 days. “Control group” was plates not added with zoledronate(0μM), and “experiment group” were plates added with different concentration of zoledronates(0, 0.01, 0.1, 0.5, 1, 3μM). Mature osteoblasts were identified with Alizarine Red staining, and protein samples were collected. Optical density was determined at wavelength of 405nm with ELISA reader. For viability analysis, cells were harvested and incubated with propidium iodide, and analysed with flow cytometry. Western blot technique was used to analyse Runx2 protein of osteoblast. Results: Secretion of bone matrix decreased as zoledronate concentration increased, and zoledronate did not effect survival rate of UMR-106 cells when measured with flow cytometer. Expression of Runx2 protein was inhibited as zoledronate concentration increased. Conclusion: From the results, we were able to identify that increase of zoledronate concentration inhibited differentiation of UMR-106 cell to osteoblast, without effecting quantity or survival rate.
참고문헌 (49)
- Menschutkin M, "Ueber die Einwirkung des Chloracetyls auf phophorige Saure", Ann Chem Pharm, 133, pp.317~320 (1865)
- Fleisch H, "The influence of pyrophosphate analogues(diphosphates) on the precipitation and dissolution", Calcif Tissue Res, pp.10~10a (1968)
- Smith R, "Paget’s disease of bone, Experience with a disphosphonate(disodium etidronate) in treatment", Q J Med, 42, pp.235~256 (1973)
- Russell RGG, "Disphosphonates in Paget’s disease", Lancet, 1(7863), pp.894~898 (1974)
- Fleisch H, "Bisphosphonates in Bone Disease. From the Laboratory to the Patient. 4th" (2000), San Diego, CA: Academic Press
- Fleisch H, "Bisphosphonates: mechanisms of action", Endocr Rev, 19, pp.80~100 (1998)
- Reid IR, "Intravenous zoledronic acid in postmenopausal women with low bone mineral density", N Engl J Med, 346, pp.653~661 (2002)
- Reid IR, "Zoledronate: efficacy and safe", J Bone Miner Res, 21, pp.83~87 (2006)
- Marx RE, "Pamidronate(Aredia) and zoledronate(Zometa) induced avascular necrosis of the jaws: a growing epidemic", J Oral Maxillofac Surg, 61(9), pp.1115~1117 (2003)
- Dimitrakopoulos I, "Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases", Int J Oral Maxillofac Surg, 35(7), pp.588~593 (2006)
- Ruggiero SL, "Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases", J Oral Maxillofac Surg, 62(5), pp.527~534 (2004)
- Migliorati CA, "Bisphophonate-assosiated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy", Cancer, 104, pp.83~93 (2005)
- Migliorati CA, "Bisphosphonate-associated osteonecrosis: a longterm complication of bisphosphonate treatment", Lancet Oncol, 7(6), pp.508~514 (2006)
- Woo SB, "Narrative review: bisphosphonates and osteonecrosis of the jaws", Ann Intern Med, 144, pp.753~761 (2006)
- 권용대, "Bisphosphonate, 구강악안면외과 영역의 새로운 위험 요소인가?", 대한악안면성형재건외과학회지, 29(5), pp.456~462 (2007), 대한악안면성형재건외과학회
- Mashiba T, "The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib", J Bone Miner Metab, 23, pp.36~42 (2005)
- Goodship AE, "Use of a bisphosphonate(pamidronate) to modulate fracture repair in ovine bone", Ann Oncol, 5(7), pp.S53~55 (1994)
- Garcia-Moreno C, "Effect of alendronate on cultured normal human osteoblasts", Bone, 22(3), pp.233~239 (1998)
- Fisher JE, "Alendronate mechanism of action: geranygeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro", Proc Natl Acad Sci USA, 96(1), pp.133~138 (1999)
- Fisher JE, "In vivo effects of bisphosphonates on the osteoclast mevalonate pathway", Endocrinology, 141, pp.4793~4796 (2000)
- Coxon FP, "Protein geranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298", J Bone Miner Res, 15(8), pp.1467~1476 (2000)
- Rogers MJ, "Cellular and molecular mechanisms of action of bisphosphonates", Cancer, 88(12), pp.2961~2978 (2000)
- Coxon FP, "The role of prenylated small GTP-binding proteins in the regulation of osteoclast function", Calcif Tissue Int, 72(1), pp.80~84 (2003)
- Martin TJ, "Metabolic properties of hormonally responsive osteogenic sarcoma cells", Clin Orthop Relat Res, 140, pp.247~254 (1979)
- Preston SJ, "Effect of methotrexate and sulphasalazine on UMR-106 rat osteosarcoma cells", Br J Rheumatol, 36(2), pp.178~184 (1997)
- Body JJ, "Treatment of Paget’s disease of bone with zoledronic acid", Rev Med Brux, 26(6), pp.513~517 (2005)
- Major PP, "Oral bisphosphonates: A review of clinical use in patients with bone metastases", Cancer, 88(1), pp.6~14 (2000)
- Brenson JR, "Lipton A, Seaman JJ. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases", Cancer, 91(10), pp.1956~ (2001)
- Hillner BE, "American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issue in Women With Breast Cancer", J Clin Oncol, 21(21), pp.4042~4057 (2003)
- Fulfaro F, "The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers", J Chemother, 17(5), pp.555~559 (2005)
- Melisi D, "Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer", Endocr Relat Cancer, 12(4), pp.1051~1058 (2005)
- Wood J, "Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid", J Pharmacol Exp Ther, 302(3), pp.1055~1061 (2002)
- Santini D, "The antineoplastic role of bisphosphonates: from basic research to clinical evidence", Ann Oncol, 14, pp.1468~1476 (2003)
- Rodan GA, "Bisphosphonates mechanisms of action", J Clin Invest, 97(12), pp.2692~2696 (1996)
- Luckman SP, "Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTPbinding proteins, including Ras", J Bone Miner Res, 13(4), pp.581~589 (1998)
- Mashiba T, "Effects of highdose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fracture", Bone, 29(3), pp.271~278 (2001)
- Whyte MP, "Bisphosphonate-induced osteopetrosis", N Engl J Med, 349(5), pp.457~463 (2003)
- Odvina CV, "Severely suppressed bone turnover: a potential complication of alendronate therapy", J Clin Endocrinol Metab, 90(3), pp.1294~1301 (2005)
- Visekruna M, "Severely suppressed bone turnover and atypical skeletal fragility", J Clin Endocrinol Metab, (3) (2008)
- Diel IJ, "Adverse effects of bisphosphonates: current issues", J Support Oncol, 5(10), pp.475~482 (2007)
- Van Poznak C, "Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates", Oncology, 20(9), pp.1053~1062 (2006)
- Pazianas M, "A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics", Clin Ther, 29(8), pp.1548~1558 (2007)
- Cafro AM, "Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid", Clin Lymphoma Myeloma, 8(2), pp.111~116 (2008)
- Hoff AO, "Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates", J Bone Miner Res, 23(6), pp.826~836 (2008)
- Khan AA, "Canadian Consensus Practice Guidelines for Bisphosphonate Associated Osteonecrosis of the Jaw", J Rhematol, (1) (2008)
- Reinholz GG, "Bisphosphonates Directly Regulate Cell Proliferation, Differentiation, & Gene Expression in Human Osteobasts", Cancer Res, 60(21), pp.6001~6007 (2000)
- Chaplet M, "Zoledronic acid upregulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition", Biochem J, 384(3), pp.591~598 (2004)
- Naidu A, "The effects of bisphosphonates on osteoblasts in vitro", Oral Surg Oral Med Oral Pathol Oral Radiol Endod, (24) (2008)
- Komori T, "Regulation of osteoblast differentiation by transcription factors", J Cell Biochem, 99(5), pp.1233~1239 (2006)